Review

Assessment of Vitamin A Supplementation Practices in Countries of the Eastern Mediterranean Region: Evidence to Implementation

Farah SAAD1, Lisa ROGERS2, Radhouene DOGGUI3,4 and Ayoub AL-JAWALDEH1,*

1 Regional Office for the Eastern Mediterranean (EMRO), World Health Organization (WHO), Monazamet El Seha El Alamia Str, Extension of Abdel Razak El Sanhouri Street, PO Box 7608, Nasr City, Cairo 11371, Egypt
2 Department of Nutrition for Health and Development, World Health Organization, Geneva, Switzerland
3 Department of Family Medicine, Université de Sherbrooke, Sherbrooke, Québec, Canada
4 Centre de Formation Médicale du Nouveau-Brunswick, Moncton, New Brunswick, Canada

(Received June 21, 2020)

Summary Vitamin A is an essential nutrient necessary for human growth and development, with critical roles in vision, immune function reproduction and maintenance of epithelial cellular integrity. Inadequate intake of vitamin A places populations at risk of developing diseases associated with vitamin A deficiency (VAD). VAD is highly prevalent across the Eastern Mediterranean Region (EMR) in children under 5 y and women of childbearing age. Therefore, infants and young children, pregnant women and postpartum women are commonly targeted by supplementation programs. Although, vitamin A supplementation has been shown to decrease preventable childhood diseases and deaths related to VAD, supplementation of vitamin A has been greatly misused in several countries within the EMR raising concern around the process of supplementing the target population. Countries across the EMR have reported different supplementation practices depending on the income level of the country, the availability of vitamin A and the prevalence rates of VAD. Although some countries had higher supplementation rates than others, the concern lies in the middle-income countries and their supplementation practices. Some of the countries across the region do not follow the World Health Organization’s (WHO) guidelines for vitamin A supplementation for the recommended age groups. The objective of this study is to assess the vitamin A supplementation practices across the countries in the EMR, determine the gaps in the supplementation practices and the issue with supplementing to healthy populations where VAD is not a public health concern, and provide recommendations for proper vitamin A supplementation within the region.

Key Words Retinol deficiency, supplementation, fortification programs, supplementation, Eastern Mediterranean Region.

Vitamin A is an essential nutrient necessary for human growth and development, with critical roles in vision, immune function, reproduction and maintenance of epithelial cellular integrity (1). Essential nutrients cannot be synthesized by the body and must therefore be provided by the diet. Vitamin A may be consumed as either preformed vitamin A or provitamin A carotenoids. Preformed vitamin A is found in animal source foods such as human and animal milk and other dairy products: glandular meats, including liver; fish liver oils; and egg yolks. Provitamin A carotenoids are found in plant sources such as green leafy vegetables, yellow vegetables, yellow and orange non-citrus fruits, red palm oil, and other indigenous plants like palm fruit found in Brazil (1). Although provitamin A carotenoids have lower amounts of biologically available vitamin A, they are more affordable than animal source foods in the Eastern Mediterranean Region (EMR). Animal products may be widely available in the region, but their high cost makes it challenging for low-income populations to consume sufficient amounts of preformed vitamin A (1). Most countries in the EMR region, are classified as low- to middle-income and their populations showed a relatively low vitamin A intakes and food sources diversity.

Young children and pregnant women are the most vulnerable to vitamin A deficiency (VAD). VAD is the main cause of preventable maternal and childhood blindness and increases the risk of mortality from common childhood diseases such as diarrhea (2). In 2013, it was estimated that 29% of children <5 y of age in low- and middle-income countries globally were vitamin A deficient (3). The prevalence of VAD varies between countries within the EMR with several being classified as having VAD of severe public health significance, defined as a ≥20% prevalence of serum retinol concentrations <0.70 μmol/L or ≥5% prevalence of
Table 1. Summary of WHO recommendations for vitamin A supplementation and the prevalence of vitamin A deficiency by population group in countries of the WHO Eastern Mediterranean Region. (11, 16, 22–26).

| Population group                              | WHO recommendation                                                                 | Settings                                                                 | Dose and frequency                                                                 | Prevalence of vitamin A deficiency | Applicable countries |
|-----------------------------------------------|------------------------------------------------------------------------------------|--------------------------------------------------------------------------|------------------------------------------------------------------------------------|-----------------------------------|----------------------|
| Neonate (first 28 d after birth)              | Not recommended as a public health intervention to reduce infant morbidity and mortality | N/A                                                                      | N/A                                                                                | None                              | N/A                  |
| Infants 1–5 mo of age                         | Not recommended as a public health intervention for the reduction of morbidity and mortality | N/A                                                                      | N/A                                                                                | None                              | N/A                  |
| Infants and children 6–59 mo of age           | Recommended in settings where vitamin A deficiency is a public health problem        | Populations where the prevalence of night blindness is 1% or higher in children 24–59 mo of age or where the prevalence of serum retinol <0.70 μmol/L is 20% or higher in infants and children 6–59 mo of age | Infants 6–11 mo (including HIV+): 100,000 IU (30 mg RE) vitamin A once Children 12–59 mo (including HIV+): 200,000 IU (60 mg RE) vitamin A every 4–6 mo | Oman: 9.5% Egypt: 12% Iran: 18.3% Jordan: 18.3% Morocco: 9.3% Palestine: 72.9% Afghanistan: 50.4% Pakistan: 39.4% Somalia: 33.3% | Iran Jordan Palestine Syria Afghanistan Pakistan Somalia |
| Infants and children with measles of age       | Recommended for all children with measles                                            | All countries, all settings                                              | Infants under 6 mo: immediately on diagnosis 50,000 IU Next day: 50,000 IU 2–4 wk later (if eye signs) 50,000 IU Infants 6–11 mo: immediately on diagnosis 100,000 IU Next day: 100,000 IU 2–4 wk later (if eye signs) 100,000 IU Children aged 12 mo and over: immediately on diagnosis 200,000 IU Next day: 200,000 IU 2–4 wk later (if eye signs) 200,000 IU | N/A                               | Iraq Lebanon Pakistan Somalia Sudan Tunisia Yemen |
| Pregnant women                                | Not recommended during pregnancy as part of routine antenatal care for the prevention of maternal and infant morbidity and mortality | N/A                                                                      | N/A                                                                                | Oman: 14.1% Palestine: 54.8% | Afghanistan Egypt Iran Jordan Pakistan Palestine Somalia |
|                                              | In areas where VAD is a severe public health problem, Vitamin A supplementation is recommended for the prevention of night blindness | Populations where the prevalence of night blindness is 5% or higher in pregnant women or 5% or higher in children 24–59 mo of age | Up to 10,000 IU daily Up to 25,000 IU weekly for a minimum of 12 wk during pregnancy until delivery | Iran: 14.1% Palestine: 54.8% | Afghanistan Egypt Iran Jordan Pakistan Palestine Somalia |
night blindness (4). Between 2004 and 2007, the prevalence of sub-clinical vitamin A deficiency was reported to be 10% in Egypt and the Syrian Arab Republic, 17% in Jordan, 20% in Morocco, 20–30% in Oman, and over 60% in Yemen, but only 2.3% in Tunisia (4). Between 2011 and 2015, the prevalence of VAD (<0.70 µmol/L retinol) among children 15–23 mo of age and 14% in pregnant women in Iran (5), 50% <0.70 µmol/L retinol among children 6–59 mo in Afghanistan in 2013 (6), and 56% <0.70 µmol/L retinol in children 0–59 mo and 43% in women of reproductive age in Pakistan in 2011 (7).

There are several interventions being implemented in areas where vitamin A deficiency is of concern. High dose vitamin A supplementation is currently one of the most widely implemented vitamin A interventions in low- and middle-income countries. It is estimated that 62% of children 6–59 mo of age in the 82 high priority countries targeted by UNICEF received the recommended two doses of high dose vitamin A supplementation in 2017 (8). Since the early 1990's, high dose vitamin A supplementation has been recommended by WHO for children 6–59 mo of age in settings where VAD is a public health problem for the reduction of morbidity and mortality related to preventable childhood diseases (9, 10). However, a more recent large study of high dose vitamin A supplementation in preschool age children in India (11) did not find a significant effect on child morbidity and mortality and some feel this intervention is no longer relevant due to reductions in the prevalence of diarrhea and diarrhea and their associated morbidity and mortality (12). An updated Cochrane systematic review of vitamin A supplementation for the prevention of morbidity and mortality in children from 6–59 mo of age reported a lower, but still significant, reduction in all-cause mortality [risk ratio (RR) 0.88; 95% confidence interval (CI) 0.83 to 0.93], mortality due to diarrhea (RR 0.88; 95% CI 0.79 to 0.98), diarrhea incidence (rate ratio 0.85; 95% CI 0.82 to 0.87), measles incidence (rate ratio 0.50; 95% CI 0.37 to 0.67), incidence of Bitot's spots (RR 0.42; 95% CI 0.33 to 0.53) and incidence of night blindness (RR 0.32; 95% CI 0.21 to 0.50) (13). As of 2011, WHO no longer recommends the use of high dose vitamin A supplementation for postpartum women or infants 1–5 mo of age (14, 15).

High-dose vitamin A supplementation has contributed to reducing child mortality rates in low- and middle-income countries but does not address the underlying problem of inadequate vitamin A intakes. Nutrition interventions such as the fortification of staple foods with vitamin A and the use of multiple micronutrient powders containing vitamin A are recommended in these settings (16, 17). Because the prevalence of VAD varies greatly with the EMR and is still a problem of public health significance in some countries, decisions to scale back or shift from universal high dose vitamin A supplementation should be based on information that verifies that vulnerable populations have adequate vitamin A status and access to sufficient dietary sources of

### Table 1. Continued

| Population group | WHO recommendation | Settings | Dose and frequency | Prevalence of vitamin A deficiency | Applicable countries |
|------------------|--------------------|----------|--------------------|-----------------------------------|----------------------|
| HIV-positive pregnant women | Not recommended as a public health intervention for reducing risk of mother-to-child transmission of HIV | N/A | N/A | N/A |
| Postpartum women | Not recommended for the prevention of maternal and infant morbidity and mortality | N/A | N/A | N/A | Afghanistan: 11.1% Egypt: 0.4% Jordan: 4.8% Oman: 0.2% Pakistan: 22.4% Palestine: 28.7% Somalia: 5.4%
Table 2. VAD prevalence rates and vitamin A supplementation practices by country (information were obtained from country representative offices within WHO EMR).

| Country income level | Country | Type of survey | Year | Prevalence of VAD | Vitamin A cut-offs | Supplementation program present? | Vitamin A supplementation dose, frequency and method | WHO guidelines followed? | Fortification |
|----------------------|---------|----------------|------|-------------------|--------------------|----------------------------------|-----------------------------------------------|-------------------------|--------------|
| High income level    | Kuwait  | N/A            | N/A  | 6–9 y:           | ≥0.9 μmol/L        | No                               | N/A                                           | ✓                       | N/A          |
|                      |         |                |      | Males 20.52%     |                    |                                  |                                               |                         |              |
|                      |         |                |      | Females 16.38%   |                    |                                  |                                               |                         |              |
|                      |         |                |      | 10–19 y:         | ≥0.9 μmol/L (10–17 y) | No                               | N/A                                           | ✓                       | N/A          |
|                      |         |                |      | Males 8.36%      | ≥1.04 μmol/L (18–19 y) |                                  |                                               |                         |              |
|                      |         |                |      | Females 9.94%    |                    |                                  |                                               |                         |              |
|                      |         |                |      | 20–49 y:         | ≥1.04 μmol/L        | No                               | N/A                                           | ✓                       | N/A          |
|                      |         |                |      | Males 2.53%      |                    |                                  |                                               |                         |              |
|                      |         |                |      | Females 9.05%    |                    |                                  |                                               |                         |              |
|                      |         |                |      | ≥50 y:           | ≥1.04 μmol/L        | No                               | N/A                                           | ✓                       | N/A          |
|                      |         |                |      | Males 4.45%      |                    |                                  |                                               |                         |              |
|                      |         |                |      | Females 3.85%    |                    |                                  |                                               |                         |              |
| Oman                 | Oman    | National Survey | 2017 | Children 6–59 mo | Deficiency: <0.7 μmol/L for children 6–59 mo | Yes, through immunization programs for children at 12 and 18 mo (not affiliated with UNICEF) | There is supplementation for children at 12 mo with a dose of 100,000 IU and 18 mo with a dose of 200,000 IU Mode: oral (capsule) Frequency: one time at 12 mo and one time at 18 mo | Supplementation recommended in Al-Sharqyah governorte (18.9%) and Al Wusta governorate (31.9%) | Mandatory Oil 18 |
|                      |         |                |      | 9.5%              |                    |                                  |                                               |                         |              |
|                      |         |                |      | Women 15–49 y:    | Deficiency: <0.7 μmol/L | Antenatal and postnatal care programs | N/A                                           |                         |              |
|                      |         |                |      | 0.2%              |                    |                                  |                                               |                         |              |
|                      |         |                |      | Insufficiency: <1.05 μmol/L |                    |                                  |                                               |                         |              |
| Bahrain, Qatar, Saudi Arabia, United Arab Emirates | N/A | N/A | No data on VAD and supplementation because it is not a public health problem | N/A | No supplementation | N/A | No supplementation | N/A | ✓ |
| Egypt                | Egypt   | Nutrition Country Profile (FAO) | 2003 | Children 6–71 mo | Severe: <0.3 μmol/L Marginal: 0.3 to <0.7 μmol/L Low: <0.7 μmol/L | Yes, through vaccination programs | 2 doses: 1. First dose, 1 vit A capsule, at 9 mo with measles vaccine 100,000 IU 2. 2 vit A capsules 200,000 IU total at 18 mo for children with activated polio | Vitamin A capsule: 200,000 IU within 28 d after delivery | — | — | — |
|                      |         |                |      | Severe 0.6%      |                    |                                  |                                               |                         |              |
|                      |         |                |      | Low 1.2%         |                    |                                  |                                               |                         |              |
|                      |         |                |      | Women of child bearing age: Severe 0.4% Marginal 10% | | | | | |
| Iraq                 | Iraq    |               |      | 15%              | Deficiency: <0.7 μmol/L | Yes, through vaccination programs | 100,000 IU with measles 200,000 IU with penta 200,000 IU preschool | — | — | — |
| Country | Income Level | Type of Survey | Year | Prevalence of VAD | Vitamin A cut-offs | Supplementation program present? | Vitamin A supplementation dose, frequency and method | WHO guidelines followed? | Fortification |
|---------|--------------|----------------|------|-------------------|-------------------|---------------------------------|-----------------------------------------------|--------------------------|--------------|
| Islamic Republic of Iran | Second Integrated Micronutrient Survey | 2012 | Children 15–23 mo: 19.1% | Deficiency: <0.7 μmol/L | Yes, with support from UNICEF | National Supplementation of vit A and D from 3–5 d until the end of 24 mo. Therefore, supplementation with Megadose applies only for children 24–59 mo. | Not recommended for pregnant and women of childbearing age unless deficiency is present or prevalence of VAD is >5% in children 24–59 mo | ✗ | — — — |
| | | | Pregnant women: 14.1% | Severe deficiency: <0.35 μmol/L | | | | | |
| | | | 2012 | Children 12–59 mo: 19.1% | Deficiency: <0.7 μmol/L | Yes, through UNICEF for Jordanian and Syrian refugees. 2 high doses of supplementation to young children first with measles vaccination and second with MMR | First dose 100,000 IU at 10 mo with measles vaccine Second shoot dose given at 18 mo with MMR | ✗ | — — — |
| | | | | Severe: 0.35 μmol/L | | | | | |
| | | | 2010 | Children 12–59 mo: 12–23: 19.7% 24–35: 17.7% 36–47: 16.5% 48–59: 2.5% | Total deficiency: 18.3% Total severe: 0.3% | | | | |
| | | | | Non-pregnant women (y): 15–19: 6.3% 20–29: 7.6% 30–39: 3.2% 40–49: 2.5% | Total deficiency: 4.8% | | | | |
| | | | | Pregnant women: 14.1% | Jordan National Micronutrient Survey | 2010 | Children 12–59 mo: 12–23: 19.7% 24–35: 17.7% 36–47: 16.5% 48–59: 2.5% | Total deficiency: 18.3% Total severe: 0.3% | | | |
| | | | | Total deficiency: 18.3% Total severe: 0.3% | Lebanon | N/A | N/A | N/A | Vitamin A supplementation provided by MoPH to enhance the effect of measles containing vaccines provided by the Expanded Program on Immunization (EPI) | N/A | Not recommended to enhance measles vaccine but to decrease active measles infection | — — — |
| Country       | Type of survey          | Year | Prevalence of VAD | Vitamin A cut-offs                                                                 | Supplementation program present? | Vitamin A supplementation dose, frequency and method                                                                 | WHO guidelines followed? | Nature | Vector | Level (mg per kg) |
|--------------|-------------------------|------|-------------------|-----------------------------------------------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------|--------------------------|--------|--------|-----------------|
| Morocco      | The Regional Survey on VAD: Ministry of Health | 1999 | 3.1% of children aged from 6 to 72 mo have a serum retinol rate < 0.3 μmol/L | Insufficient: < 0.3 μmol/L; Low: 0.3–0.7 μmol/L; Normal: > 0.7 μmol/L | Yes, a micronutrient supplementation program for children and women according to a national schedule. This intervention is integrated into the national nutrition program | 3 doses for children under five: 1. First dose at 6 mo (100,000 IU) 2. Second dose at 12 mo (200,000 IU) 3. Third dose at 18 mo (200,000 IU) | ✓ | — | — | — |
| Palestine    | Micronutrient Survey    | 2019 | Children aged 6 mo to 12 y showed that 9.3% of children have a low serum vitamin A level (< 0.7 μmol/L), including 2.1% have insufficient serum levels (< 0.35 μmol/L) | Insufficient: < 0.35 μmol/L; Low: < 0.70 μmol/L; Normal: ≥ 0.70 μmol/L | Yes, only for children 0–12 mo old | Two drops per day of vitamin A and D each drop containing 500 IU vitamin A and 200 IU vitamin D | Not recommended for 0–5 mo | — | — | — | — |
| Pregnant women: 54.8% | | | | Individual cut-off points: < 1.05 μmol/L; Markedly low: < 0.7 μmol/L; Low: < 1.05 μmol/L | | | | |
| Lactating mothers: 28.7% | | | | Individual cut-off points: < 1.05 μmol/L; Markedly low: < 0.7 μmol/L; Low: < 1.05 μmol/L | | | | |
| Children 6–59 mo: 72.9% | | | | Individual cut-off points: < 1.05 μmol/L; Markedly low: < 0.7 μmol/L; Low: < 1.05 μmol/L and ≥ 0.7 μmol/L | | | | |
| Adolescent males: 42.6% | | | | Individual cut-off points: < 1.05 μmol/L; Markedly low: < 0.7 μmol/L; Low: ≥ 0.7 μmol/L and < 1.05 μmol/L | | | | |
| Adolescent females: 57% | | | | Individual cut-off points: < 1.05 μmol/L; Markedly low: < 0.7 μmol/L; Low: ≥ 0.7 μmol/L and < 1.05 μmol/L | | | | |
| Country income level | Country | Type of survey | Year | Prevalence of VAD | Vitamin A cut-offs | Supplementation program present? | Vitamin A supplementation dose, frequency and method | WHO guidelines followed? | Fortification | Nature | Vector | Level (mg per kg) |
|----------------------|---------|----------------|------|-------------------|-------------------|---------------------------------|--------------------------------------------------|------------------------|--------------|--------|--------|-----------------|
| Tunisia              | Tunisia | Population based study: Centre we of Tunisia | 2010 | Children aged 5–7: | Plasma vitamin A (mmol/L) | No, according to the results of the survey conducted in the poorest region of the country, it is presumed that VAD is not a public health problem | 2 doses of vitamin A: 200,000 IU from 2–5 y old 3 doses of vitamin A: 100,000 IU at 6 mo, 200,000 IU at 12 mo and 200,000 at 18 mo | No | ✓ | — | — | — |
| Syrian Arab Republic | N/A     | N/A            | N/A  | N/A               | N/A               | Yes, through vaccination programs at ages 6, 12 and 18 mo old | Emergency setting | — | — | — | — |
| Afghanistan Low income | Afghanistan National Nutrition Survey | 2013 | Children 6–59 mo: | Plasma vitamin A (mmol/L) | Yes, through vaccination program, only for children not covered/missed during National Immunization Day (NID) | Yes, through NID 6–12 mo age, 100,000 IU every 6 mo 12 mo-5 y age, 200,000 IU every 6 mo Children with measles: 6–12 mo age, 100,000 IU on day one, two and 14 | ✓ | Voluntary Oil | 9 |
|                       | Women 15–49 y: |                       |      | Plasma vitamin A (mmol/L) | No | N/A | — | — | — | — |
|                       | 50.4%    | 45.8% mild VAD 4.6% severe VAD | Plasma vitamin A (mmol/L) | No | N/A | — | — | — | — |
|                       | 11.3%    | 10.8% mild VAD 10% severe VAD | Plasma vitamin A (mmol/L) | No | N/A | ✓ | — | — | — |
|                       | 12.1%    | 12% moderate deficiency: 39.4% Non-deficient: 48.5% | Plasma vitamin A (mmol/L) | No | N/A | — | — | — | — |
|                       | 4.9%     | 4.9% moderate deficiency: 22.4% Non-deficient: 72.7% | Plasma vitamin A (mmol/L) | No | N/A | — | — | — | — |
| Pakistan              | Pakistan National Nutrition Survey | 2018 | Children 6–59 mo: | Serum retinol level | Yes | For children 6 to 59 mo, twice a year at 6 monthly intervals along with polio SIAs. No other supplementation. Vitamin A fortification of Edible Oil and Ghee | ✓ | Mandatory Oil | 11.7 |
| Country           | Type of survey                                      | Year    | Prevalence of VAD | Vitamin A cut-offs | Supplementation program present? | Vitamin A supplementation dose, frequency and method                                                                 | WHO guidelines followed? | Fortification Nature | Vector | Level (mg per kg) |
|------------------|-----------------------------------------------------|---------|-------------------|--------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------|--------------------------|---------------------|---------|------------------|
| Somalia          | National Micronutrient and Anthropometric Nutrition Survey | 2009    | Children 6–59 mo 33.3% | Deficiency: <0.825 μmol/L | Yes, through supplementation programs | Infants 6–11 mo and children 12–59 mo: single dose every 4–6 mo at 100,000 IU and 200,000 IU respectively                 | ✓                        | —                   | —                   | —                 |
|                  |                                                    |         |                   |                    |                                  |                                                                                                                            |                          |                     |                     |                   |
| Somalia          |                                                    |         | School-aged children: 31.9% |                    |                                  | N/A                                                                                                                       |                          |                     |                     |                   |
|                  |                                                    |         | Women of reproductive age (15–49 y): 54.4% | Deficiency: <1.24 μmol/L | N/A                              | Single dose of 200,000 IU within the first 6 wk of delivery                                                               |                          |                     |                     |                   |
| Sudan            | Post-partum women: 13.5%                            | <1%     |                   |                    | Yes, through NIDS vaccination campaigns twice a year. Vitamin A supplementation through polio eradication programs. | Infants and children (6–11 mo): 100,000 IU twice a year. Children 12–59 mo: 200,000 IU twice a year. Pregnant women: no supplementation unless VAD then 50,000 IU or as prescribed by doctor. Postpartum women: 200,000 IU within forty days after delivery; frequency depends on repetition of the pregnancy. | ✓                        | —                   | —                   | —                 |
| Yemen            | N/A                                                 | N/A     |                   |                    | Yes. Types: Routine supplementation: along with routine EPI with MR doses at the age of 9 and 18 mo old. Campaign style supplementation: along with polio/measles campaigns. Usually for two doses a year if the campaigns are implemented as planned. | Children 6–11 mo: 100,000 IU. Children 12–59 mo: 200,000 IU. The mode and frequency are as explained earlier. | ✓                        | Mandatory          | Oil                 | 18                |
vitamin A. The Global Alliance for Vitamin A (18) has developed a process for helping countries to gather and evaluate the necessary evidence to aid countries in adapting the WHO guidelines on high dose vitamin A supplementation in infants and children 6–59 mo of age.

The aim of this paper is to review the WHO guidelines on vitamin A interventions and assess the current vitamin A supplementation practices across the EMR. As supplementation practices and the prevalence of VAD across the region is inconsistent, this review highlights that high dose supplementation is being provided to populations where VAD is not of public health concern. Gaps in supplementation practices are also identified to improve programmes within the region in compliance with WHO recommendations.

**Methodology**

The most current WHO guidelines for vitamin A supplementation in different age groups were retrieved from the WHO e-Library of Evidence of Nutrition Actions (19). A literature search was conducted to identify the most recent national nutrition surveys, as well as publications from UNICEF and the United Nations Food and Agriculture Organization (FAO) describing vitamin A supplementation practices in countries within WHO EMR. In addition, data on the vitamin A status of populations was retrieved using the Micronutrients Database in the WHO Vitamin and Mineral Nutrition Information System (20). Representatives from all 22 countries within WHO EMR were contacted to complete a questionnaire regarding the vitamin A status of their population, whether or not vitamin A supplementation programmes were being implemented, and if so, at what the dose, frequency and method of supplementation.

Countries within WHO EMR were classified by income. The categories include low, middle- and high-income countries. Afghanistan, Djibouti, Libya, Pakistan, Somalia, Sudan and Yemen are categorized as low-income countries. The middle-income countries in the region include Egypt, Iraq, Islamic Republic of Iran, Jordan, Lebanon, Morocco, Palestine, Syrian Arab Republic and Tunisia. High-income countries include Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and United Arab Emirates.

**Results**

The most recent guidance on vitamin A supplementation for different population groups was published in 2011. Recommendations are available by the following life stages: neonate (first 28 d of life), infants aged 1–5 mo, infants and children aged 6–59 mo, pregnant women, pregnant women living with Human Immunodeficiency Virus (HIV), postpartum women, and infants and children with measles. Table 1 (10, 15, 21–25) summarizes the recommendations based on age group, settings, dose and frequency of supplementation and route of administration. In addition, the prevalence of VAD in each country in the EMR is added to each age group with a column of the countries that are recommended to supplement with vitamin A.

Information from 20 out of the 22 countries was available and the practices were compared with the WHO guidelines to determine if countries were following the recommended guidelines.

Countries across the EMR have revealed different supplementation practices depending on the income level of the country, the availability of vitamin A and the prevalence rates of VAD (Table 2) (e.g. Islamic Republic of Iran (26)). Although some countries had higher supplementation rates than others, the concern lies in the middle-income countries and their supplementation practices. Some of the countries across the region do not comply with the WHO guidelines for vitamin A supplementation for all recommended age groups. Throughout the analysis of the data, it was witnessed that the cut-off points used across countries within the EMR are different. The majority diagnosed deficiency when the serum retinol levels were <0.7 μmol/L, marginal when levels were between 0.3 to <0.7 μmol/L, and classified as severely deficient when levels were <0.3 μmol/L. However, countries including Kuwait, Palestine and Somalia, diagnosed deficiency when vitamin A levels were <1.05 μmol/L. This can create a differentiation between the data related to prevalence rates between countries since rates could be lower if different cut-offs are used.

High-income countries have little or no data related to VAD or supplementation practices because VAD is not a public health problem or non-existent in countries like Bahrain, Qatar, Saudi Arabia and United Arab Emirates. In this case, no supplementation programs are present in these countries. Kuwait has available data on the prevalence of VAD between the ages 6–50 y old in males and females. The prevalence among 10–19, 20–49, and ≥50 y old is minor with all rates <10%. The only age group that had higher levels of deficiency was 6–9 y old where the prevalence of VAD in males is 20.25% and 16.38% in females. However, since it is not considered a public health problem, Kuwait does not have a supplementation program present meaning they are following the recommended WHO guidelines.

Oman is the only high-income country that raises questions when it comes to their vitamin A supplementation practices. As a high-income country with access to high-quality diets rich in vitamin A foods, the prevalence among children ages 6–59 mo (9.5%) and women 15–49 y old (0.2%) which is relatively low. Although rates are low, Oman supplements children at ages 12 (100,000 IU) and 18 (200,000 IU) mo through immunization programs, and women through antenatal and postnatal programs. This does not comply with the WHO guidelines since the prevalence of VAD among children is not ≥20%. After taking a deeper look into the current situation in Oman, it has been noticed that governorates like Al-Sharqyah and Al Wusta have high rates of deficiency with rates of 18.9% and 31.9%, respectively.

Unlike high-income countries in the EMR, the mid-
dle-income countries face the greatest discrepancies in the rates of VAD and their supplementation practices. In most middle-income countries including Egypt, Islamic Republic of Iran, Jordan and Tunisia, VAD is considered to be a mild-to-moderate public health problem. However, in Palestine and Morocco, VAD is classified as a severe public health problem with prevalence rates of 72.9% and 37.8% among children 6–59 mo, respectively. The prevalence of VAD in Egypt is 12% for children 6–71 mo and are being supplemented with vitamin A at 9 mo when the measles vaccination is introduced, and then a second dose at 18 mo only for children with activated polio. However, there is no evidence that correlates vitamin A supplementation with treating polio. Since the 1990s vitamin A supplementation has been linked with polio National Immunization Days (NIDs), as a vehicle to reach children. The most affected ones by VAD are the African Region (36% (95% CI: 9–67) in 2013) and South East Asian Region (47% (95% CI: 24–73) in 2013) (3). The noticeable reduction in VAD was denoted in the Western Pacific Region from 40% (95% CI: 14–73) in 1991 to 6% (95% CI: 1–6) in 2013 while prevalence still consistently the same for the Eastern Mediterranean Region.

Discussion

Although some high-to-middle income countries across the EMR consume relatively healthy diets, VAD remains a burden on most low-income countries and a few middle-income countries. Despite the burden and the efforts made to supplement with vitamin A in order to improve the status of those most vulnerable, countries continue to misinterpret the recommended guidelines suggested by WHO. Previously, countries were advised to supplement with vitamin A to reduce morbidity and mortality rates among infants, children and pregnant women. UNICEF collaborated with several immunization programs to provide two high doses of vitamin A. By taking this initiative, it increased the coverage rates in low-income countries. Low-income countries need access to vitamin A supplements. Although a lot of progress has been made over the past two decades, supplementation has recently become more difficult. This is because as the world works to eradicate polio, many countries have discontinued the implementation of polio immunization programmes. In low-income countries, these programmes are the vehicle for delivery of vitamin A supplements (28).

Since supplementation is not always available in low-income countries, it is important to consider other methods of preventing and treating VAD. One of the most common and efficient methods includes fortification of staple foods. Vitamin A is one of many vitamins and minerals that is added to staple foods including vegetable oil, wheat flour, rice, sugar and many more. At the time of study only 3 countries (Afghanistan, Pakistan and Yemen) have issued standards for the fortification of oil with vitamin A. Low compliance was reported in Afghanistan as low as 30% while it reaches 68% in Pakistan. Wheat flour could be fortified with vitamin A since it is stable in flour and does not affect the smell, taste and appearance of the flour. However, throughout the preparation of wheat flour, the vitamin A content could be affected due to high humidity and temperatures (29), WHO has constructed recommendations on the average levels of nutrients to add to wheat flour based on extraction, fortification compound and per capita flour availability (30). It is recommended to fortify with vitamin A palmitate at different levels based on average per capita wheat flour availability. The recommendations are based on population at risk of VAD. However, since vegetable oil is highly consumed in the EMR, fortification of vegetable oil with vitamin A would be the most cost-effective technique to aid in the improvement of vitamin A status.

In addition to fortification, efforts should be made to increase awareness on the importance of consuming a balanced and healthy diet that includes the intake of fruits, vegetables, protein, carbohydrates and fats. A healthy lifestyle starts off with breastfeeding. Mothers in low, middle- and high-income countries should be encouraged to breastfeed to support the needs of their infants. Breast milk is a rich source of vitamin A that adjusts to the amount an infant requires.

The current vitamin A situation and trend during the last three decades vary across the WHO regions. Indeed, the most affected ones by VAD are the African Region (47% (95% CI: 24–73) in 2013) and South East Asian Region (36% (95% CI: 9–67) in 2013) (3). The noticeable reduction in VAD was denoted in the Western Pacific Region from 40% (95% CI: 14–73) in 1991 to 6% (95% CI: 1–6) in 2013 while prevalence still consistently the same for the Eastern Mediterranean Region.
over the period of 1991–2013 or increased slightly in African Region (+4%) (3). The Regions of Americas VAD prevalence decreased by 10% since 1991 to reach 11% (95% CI: 4–23) in 2013. In 2017, the number of Disability-Adjusted Life Years (DALYs) reach more than one million in two regions, namely Africa Region and South-East Asia Region (Global Health Data Exchange, http://ghdx.healthdata.org/). However, the number of DALYs declined over the last three decades.

Some limitations to this study include the difference in the cut-off points of serum retinol used to identify VAD. With countries using different cut-offs it makes it difficult to compare VAD across the region. Some rates could potentially be higher or lower depending on the cut-offs used. In addition, the data on VAD has not been updated in all countries within the region. Each country has information from different years, which could be another limitation when analyzing the data. The available data across the EMR varies in the age groups studied in countries. Most countries have studied infants and children ages 6–59 mo, pregnant women and women of childbearing age. However, some countries only have data available on older children and adolescents. This limits the analysis of the results as two age groups cannot be compared to one another.

In conclusion, to support Member States to appropriately follow and implement the WHO guidelines for vitamin A supplementation, there are a few recommendations to help the EMR. After investigating the current situation of VAD and supplementation practices in the region recommendations for countries with different income levels differ.

For high income countries, it is not recommended to supplement with vitamin A since deficiency is extremely low or non-existent. However, in countries like Oman where VAD is not a public health problem but concerning levels of VAD are present in some governorates where nomads reside, it is recommended to only implement supplementation programs that comply with the WHO guidelines in Al-Sharqyah and Al Wusta.

The first step-in middle-income countries to change current practices is to identify if the country needs a supplementation program or not by looking at the prevalence of deficiency and matching it with the WHO recommendations. There is a need to re-evaluate the target population that focus on targeted populations where VAD is a public health concern. Since the highest rates of deficiency are among children 6–59 mo, middle income countries should focus on only supplementing children in populations where the prevalence of night blindness is $\geq 1\%$ in children 24–59 mo of age or where the prevalence of VAD is $\geq 20\%$ in infants and children 6–59 mo of age, using the cut-off $<0.7 \mu\text{mol/L}$. Dose, frequency and method should also comply with WHO guidelines. This applies to Eastern Mediterranean countries including Iran, Jordan, Morocco, Palestine and Syria.

As for low income countries, since all Eastern Mediterranean countries under this category comply with the WHO guidelines, it is recommended to continue to supplement with vitamin A in parallel with the recommendations. If any improvements take place in low-income countries, it is recommended to re-evaluate supplementation practices to determine if supplementation is still needed in specific age groups or governorates.

As an overall recommendation for all countries in the EMR, countries should work towards increasing awareness on consuming a healthy diet rich in various vitamins and mineral including vitamin A rich foods. In addition, it is highly recommended to improve the status of vitamin A through fortification programs focused on fortifying wheat flour, rice or vegetable oil.

Authorship

Review concept and design: AA and FS, interpretation: FS, LR, RD and AA, writing manuscript: FS, RD, LR and AA.

Disclosure of state of COI

No conflicts of interest to be declared.

Acknowledgments

This review is funded by the Eastern Mediterranean Regional Office of the World Health Organisation.

REFERENCES

1) WHO. 2004. Vitamin and mineral requirements in human nutrition. World Health Organization and Food and Agriculture Organization of the United Nations.
2) UNICEF 2020. UNICEF global databases, based on administrative reports from countries. Vitamin A supplementation coverage 2000–2018 for current priority country list.
3) Stevens GA, Bennett JE, Hennocq Q, Lu Y, De-Regil LM, Rogers L, Danaei G, Li G, White RA, Flaxman SR, Oehrle SP, Finucane MM, Guerrero R, Bhutta ZA, Then-Paulino A, Fawzi W, Black RE, Ezzati M. 2015. Trends and mortality effects of vitamin A deficiency in children in 138 low-income and middle-income countries between 1991 and 2013: a pooled analysis of population-based surveys. Lancet Glob Health 3: e528–e536.
4) Bagnchi K. 2008. Nutrition in the eastern Mediterranean region of the world Health Organization. East Mediterr Health J 14: S107–S113.
5) Pouraram H, Dizayery A, Mohammad K, Parsaeian M, Abdollahi Z, Motlagh AD, Djalali M, Khodaverdian K, Soloudeh G, Yarpavari A, Heshmat R, Siassi F. 2018. Second national integrated micronutrient survey in Iran: Study design and preliminary findings. Arch Iran Med 21: 137.
6) Ministry of Public Health (Afghanistan), UNICEF. 2014. National Nutrition Survey Afghanistan 2013. Ministry of Public Health, Kabul.
7) Government of Pakistan. 2013. National Nutrition Survey 2011. Planning and Development Division, Government of Pakistan, Islamabad.
8) UNICEF 2019. The State of the World’s Children 2019. Children, Food and Nutrition: Growing well in a changing world. UNICEF, New York.
9) WHO/UNICEF/IVACG Task Force. 1997. Vitamin A supplements: a guide to their use in the treatment and prevention of vitamin A deficiency and xerophthalmia. World Health Organization, Geneva.
10) WHO. 2011. Guideline: vitamin A supplementation in infants and children 6–59 months of age. World Health Organization, Geneva.

11) Awasthi S, Peto R, Read S, Clark S, Pande V, Bundy D. DEVTA (Deworming and Enhanced Vitamin A) Team. 2013. Vitamin A supplementation every 6 months with retinol in 1 million pre-school children in north India: DEVTA, a cluster-randomised trial. Lancet 381: 1469–1477.

12) Mason JB, Sanders D, Greiner T, Shrimpton R, Yukich J. 2016. Vitamin A deficiency: policy implications of estimates of trends and mortality in children. Lancet Glob Health 4: e21.

13) Imdad A, Mayo-Wilson E, Herzer K, Bhutta ZA. 2017. Vitamin A supplementation for preventing morbidity and mortality in children from six months to five years of age. Cochrane Database Syst Rev 3: Cd008524.

14) Oliveira-Menegozzo JM, Bergamaschi DP, Middleton P, East CE. 2010. Vitamin A supplementation for postpartum women. Cochrane Database Syst Rev 10: CD005944.

15) WHO. 2011. Vitamin A supplementation for infants 1–5 months of age. World Health Organization, Geneva.

16) WHO. 2019. Multiple micronutrient powders for point-of-use fortification of foods consumed by children 2–12 years of age. World Health Organization [update February 11th, 2019].

17) WHO. 2019. Multiple micronutrient powders for point-of-use fortification of foods consumed by children 6–23 months of age. World Health Organization [update February 11th, 2019].

18) The Global Alliance for Vitamin A. 2019. Conditions for scaling back universal preschool vitamin A supplementation. Policy Brief.

19) Khan WU, Sellen DW. 2011. e-Library of Evidence for Nutrition Actions (eLENA). World Health Organization, Geneva.

20) WHO. 2011. Vitamin and Mineral Nutrition Information System (VMNIS).

21) WHO. 2011. Guideline: Neonatal vitamin A supplementation. World Health Organization, Geneva. p 1–9.

22) WHO. 2019. Essential nutrition actions: mainstreaming nutrition through the life-course. World Health Organization, Geneva.

23) WHO. 2011. Guideline: vitamin A supplementation in pregnant women. World Health Organization, Geneva.

24) WHO. 2011. Vitamin A supplementation in pregnancy for reducing the risk of mother-to-child transmission of HIV. World Health Organization, Geneva.

25) WHO. 2011. Vitamin A supplementation in postpartum women. World Health Organization, Geneva.

26) Pouraram H, Djazayery A, Mohammad K, Parsaeian M, Abdollahi Z, Dorosty Motlagh A, Djalali M, Khodaverdian K, Sotoudeh G, Yarparvar A, Heshmat R, Siassi F. 2018. Second National Integrated Micronutrient Survey in Iran: Study design and preliminary findings. Arch Iran Med 21: 137–144.

27) UNICEF. 2007. Vitamin A Supplementation: A decade of progress. The United Nations Children’s Fund (UNICEF).

28) The Lancet. 2018. Vitamin A Supplementation: A decade of progress. The United Nations Children’s Fund (UNICEF).

29) The Lancet. 2018. Vitamin A distribution in danger. Lancet 391: 1866.

30) WHO. 2009. Recommendations on wheat and maize flour fortification meeting report: Interim consensus statement. World Health Organization, Geneva.

31) Al Jawaldeh A, Pena-Rosas JP, McColl K, Johnson Q, Elmadfa I, Nasreddine L. 2019. Wheat flour fortification in the Eastern Mediterranean Region. WHO Regional Office for the Eastern Mediterranean, Cairo.